I recently had the pleasure of speaking to David Green, the CEO of Harvard Apparatus Regenerative Technology (HART). Please listen to that interview here either before or after reading this, as it supplements the content of this article. This company is pre-revenue, so it is not one that I would typically invest in or value. However, I am open to all investment ideas, and this one has a few important exceptions that made me pay attention. Notably, the company has demonstrated proof of concept, holds numerous patents, and is the first mover in a $600 million market all while sporting a tiny market cap.
HART was recently spun off of Harvard Bioscience (NASDAQ:HBIO). The company is currently working...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|